Enhertu is finally available on the NHS in England. That’s the headline this week, and it’s the kind of headline breast cancer patients here have been waiting more than two years for
Enhertu NHS Approval: What Changed in England
On September 17, NICE announced that Enhertu (trastuzumab deruxtecan) will be offered through the NHS in England to adults with HER2-low metastatic or unresectable breast cancer. It’s the drug’s first positive recommendation in England after two-plus years of stalled price negotiations between NICE, NHS England, and manufacturers AstraZeneca and Daiichi Sankyo. Scotland has covered it since 2023. England has not — until now.
The reversal came down to money, not science. NICE had already said the clinical evidence was compelling: Enhertu helps people live longer and slows disease progression compared with standard chemotherapy. What changed was the threshold NICE uses to decide what counts as cost-effective, raised as part of a UK-US pharmaceutical pricing agreement struck in December 2025. A new method for assessing quality of life, published in late August, helped clear the rest of the path.
About 1,000 women a year are expected to be eligible. Breast Cancer Now called it “a momentous day” — and also didn’t let the moment pass without naming its cost. Thousands of people missed access during the standoff. Some of them died waiting.
FDA Approves Etcamah for ESR1-Mutated Breast Cancer
Days earlier, on September 4, the FDA granted accelerated approval to Etcamah (camizestrant), used alongside a CDK4/6 inhibitor for adults with HR-positive, HER2-negative advanced or metastatic breast cancer whose tumors have developed an ESR1 mutation — a common way these cancers learn to resist standard hormone therapy. In trials, switching to Etcamah more than doubled the time patients went without their disease progressing (16 months versus 9.2 months).
What’s genuinely new here is the trigger for treatment: Etcamah is the first cancer therapy approved based on detecting a resistance mutation in a blood test, before scans show the cancer is growing. Catching resistance early, instead of waiting for it to show up on imaging, could mean fewer people staying too long on a drug that’s quietly stopped working for them.
Why These Breast Cancer Treatment Approvals Matter
Neither of these announcements changes anything about the parts of this journey no drug touches — the fear, the waiting, the 2 a.m. questions nobody thought to ask at the appointment. But they matter. More time, and better-targeted time, are the two things almost every person I’ve talked to on this road says they want most.
If you’re navigating a breast cancer diagnosis and want to talk through what a new treatment option means for your own situation, askellyn.ai is there day or night — remember, she’s not a substitute for your oncology team, but she can help you sit with the news and prepare better questions for your next appointment.
FAQ
Who is eligible for Enhertu on the NHS in England?
Adults with HER2-low metastatic or unresectable breast cancer who’ve had prior chemotherapy for metastatic disease, or whose cancer recurred during or within six months of completing adjuvant chemotherapy. NICE estimates around 1,000 women a year will qualify.
What is Etcamah (camizestrant) used for?
It’s approved for adults with HR-positive, HER2-negative advanced or metastatic breast cancer who develop an ESR1 mutation — detected via blood test — while on aromatase inhibitor and CDK4/6 inhibitor therapy. It’s used in combination with a CDK4/6 inhibitor.
Is Enhertu available for HER2-positive breast cancer too?
Yes — patients with HER2-positive cancers have had NHS access to Enhertu in England already. This new approval specifically covers the HER2-low group, which had been excluded.
— Ellyn
Sources: NICE, September 17, 2026; FDA press release, September 4, 2026.
Alt text for header image: Enhertu breast cancer drug now available on NHS England 2026
Want this as a downloadable file for your CMS, or is copy-paste from here fine?
